Compare GERN & PMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GERN | PMT |
|---|---|---|
| Founded | 1990 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 812.7M |
| IPO Year | 1996 | 2009 |
| Metric | GERN | PMT |
|---|---|---|
| Price | $0.99 | $7.83 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 8 |
| Target Price | $3.63 | ★ $10.17 |
| AVG Volume (30 Days) | ★ 13.5M | 3.1M |
| Earning Date | 11-04-2026 | 10-29-2026 |
| Dividend Yield | N/A | ★ 19.44% |
| EPS Growth | ★ 51.85 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,065,000.00 | ★ $351,067,000.00 |
| Revenue This Year | $27.99 | N/A |
| Revenue Next Year | $44.91 | $27.13 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.84 | $6.70 |
| 52 Week High | $2.01 | $13.80 |
| Indicator | GERN | PMT |
|---|---|---|
| Relative Strength Index (RSI) | 42.18 | 54.32 |
| Support Level | $0.84 | $6.70 |
| Resistance Level | $1.67 | $9.80 |
| Average True Range (ATR) | 0.09 | 0.27 |
| MACD | -0.00 | 0.18 |
| Stochastic Oscillator | 42.50 | 65.50 |
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
PennyMac Mortgage Investment Trust is a specialty finance company that invests mainly in residential mortgage loans and mortgage-related assets. The company's operations include activities such as the production and servicing of financial securities based on residential loans and the pooling and reselling of high-credit-quality mortgages. The company operates through three segments: correspondent production, credit-sensitive strategies, interest-rate-sensitive strategies. The Credit sensitive strategies segment generates income via investments in CRT arrangements, subordinate MBS, distressed loans, and real estate.